<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2891">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539795</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300005845</org_study_id>
    <nct_id>NCT04539795</nct_id>
  </id_info>
  <brief_title>COVID-19 Study of Safety and Tolerability of Alvelestat</brief_title>
  <acronym>COSTA</acronym>
  <official_title>A Phase Ib/II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (&gt; 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mereo BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK),&#xD;
      and explore the mechanistic and clinical effect of alvelestat (an oral neutrophil elastase&#xD;
      inhibitor) orally twice per day for 10 days added to standard of care in adult patients (≥18&#xD;
      years) with COVID-19 respiratory disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers and % of subjects who experience at least 1 treatment-emergent adverse event</measure>
    <time_frame>to day 60</time_frame>
    <description>Safety Outcome Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>to Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events of special interest</measure>
    <time_frame>to Day 14 (acute treatment period) or EoT</time_frame>
    <description>clinically significant safety monitoring labs tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of alvelestat on blood pharmacodynamic biomarkers of inflammation</measure>
    <time_frame>to day 10</time_frame>
    <description>neutrophil elastase</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Placebo oral tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alvelestat oral tablet - dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MPH966</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alvelestat oral tablet - dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MPH966</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alvelestat oral tablet - dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MPH966</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvelestat</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Alvelestat oral tablet - dose 1</arm_group_label>
    <arm_group_label>Alvelestat oral tablet - dose 2</arm_group_label>
    <arm_group_label>Alvelestat oral tablet - dose 3</arm_group_label>
    <other_name>MPH966</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Placebo oral tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Proven SARS-Cov-2 infection (confirmed by PCR from a nasopharyngeal or lower&#xD;
             respiratory tract sample)&#xD;
&#xD;
          -  A score of Grade 3 to 5 on the WHO 9-point Ordinal Scale&#xD;
&#xD;
          -  Male participants must agree to use a highly effective contraception during the&#xD;
             treatment period and for at least 4 days after the last dose of study treatment and&#xD;
             refrain from donating sperm during this period.&#xD;
&#xD;
          -  Female participants are eligible to participate if not pregnant; not breastfeeding;&#xD;
             and at least one of the following conditions is met:&#xD;
&#xD;
        Not a woman of childbearing potential OR A woman of childbearing potential who agrees to&#xD;
        follow the contraceptive guidance during the treatment phase and for at least 4 days after&#xD;
        the last dose of study medication - Capable of giving signed informed consent which&#xD;
        includes a commitment to comply with the requirements and restrictions listed in the&#xD;
        informed consent form (ICF) and within this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have previously had a score of 6 or 7 on the WHO 9-point Ordinal Scale&#xD;
&#xD;
          -  Patients who require support with invasive mechanical ventilation at the time of&#xD;
             inclusion, or expected to be required within 24 hours of randomization&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) OR aspartate aminotransferase (AST) &gt;2 × the upper&#xD;
             limit of normal (ULN) OR Total Bilirubin &gt; ULN. In patients with a documented history&#xD;
             of Gilbert's Syndrome AND baseline total bilirubin elevation consistent with an&#xD;
             exacerbation of Gilbert's Syndrome (i.e. no other cause of total bilirubin elevation),&#xD;
             subjects may enroll if total bilirubin is &lt; 5x ULN.&#xD;
&#xD;
          -  Diagnosis of liver cirrhosis, esophageal varices, ascites or hepatic encephalopathy&#xD;
&#xD;
          -  Chronic liver diseases such as autoimmune hepatitis, primary biliary cholangitis,&#xD;
             primary sclerosing cholangitis, Wilson's disease, haemochromatosis&#xD;
&#xD;
          -  Significant renal disease or infection (as determined by the Investigator) including&#xD;
             stage 4 chronic kidney disease or estimated glomerular filtration rate &lt;60mL/min&#xD;
&#xD;
          -  Absolute neutrophil count ≤ 1000/µL at screening&#xD;
&#xD;
          -  Myocardial infarction, transient ischemic attack or stroke within 3 months prior to&#xD;
             the first dose&#xD;
&#xD;
          -  Current unstable angina or congestive heart failure (New York Heart Association&#xD;
             III/IV)&#xD;
&#xD;
          -  Screening 12-lead EKG with a measurable QTc interval according to Fridericia&#xD;
             correction (QTcF) &gt;450 ms&#xD;
&#xD;
          -  Anticipated transfer to another hospital that is not the study center within 24 hours&#xD;
&#xD;
          -  Allergy to study medication or excipients&#xD;
&#xD;
          -  Inability to swallow tablets&#xD;
&#xD;
          -  Other documented comorbidities or laboratory abnormalities that in the opinion of the&#xD;
             Investigator could affect the outcome of the study assessments, participant safety, or&#xD;
             ability of the participant to comply with the requirements of the protocol&#xD;
&#xD;
          -  Any patient whose interests are not best served by study participation, as determined&#xD;
             by the Investigator&#xD;
&#xD;
        Excluded Prior/Concomitant Therapy&#xD;
&#xD;
          -  Requirement for medications mainly metabolized by CYP2C9 and with narrow therapeutic&#xD;
             index (eg, warfarin, phenytoin) is prohibited unless therapeutic monitoring available&#xD;
             for duration of alvelestat dosing&#xD;
&#xD;
          -  Medicines that are potent CYP3A4 inhibitors including (but are not limited to)&#xD;
             clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, ritonavir,&#xD;
             verapamil and potent inducers including but not limited to phenobarbital, phenytoin&#xD;
             and rifampicin, will be exclusionary&#xD;
&#xD;
          -  Requirement for medications substantially reliant on OATP1B1 for metabolism where&#xD;
             discontinuation during study drug administration is not possible or where fluctuations&#xD;
             in levels are considered clinically important (as per investigator judgement) and&#xD;
             cannot be clinically monitored (e.g., statins, valsartan, olmesartan, enalapril,&#xD;
             repaglinide)&#xD;
&#xD;
        Excluded Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
        - Participation in any clinical investigation using investigational treatments within 4&#xD;
        weeks or 5 half-lives of the drug (whichever is longer) prior to the initial dosing (or&#xD;
        longer if required by local regulations) is prohibited. Use of remdesivir (Veklury) under&#xD;
        the conditions of the authorization for emergency use in the US, and per manufacturer's&#xD;
        instructions, is permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M Wells, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James M Wells, MD</last_name>
    <phone>205-934-5555</phone>
    <email>jmwells@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark T Dransfield, MD</last_name>
    <phone>205-934-5555</phone>
    <email>mdransfield@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAB Lung Health Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James M Wells, MD</last_name>
      <phone>205-934-5555</phone>
      <email>jmwells@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mark Dransfield, MD</last_name>
      <phone>205-934-5555</phone>
      <email>mdransfield@uabmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>James Michael Wells</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

